|1.||Auchampach, John A: 2 articles (09/2008 - 01/2008)|
|2.||Wan, Tina C: 2 articles (09/2008 - 01/2008)|
|3.||Tracey, W Ross: 2 articles (01/2008 - 12/2003)|
|4.||van der Hoeven, Dharini: 1 article (09/2008)|
|5.||Bienengraeber, Martin W: 1 article (01/2008)|
|6.||Tampo, Akihito: 1 article (01/2008)|
|7.||Gross, Garrett J: 1 article (01/2008)|
|8.||Kwok, Wai-Meng: 1 article (01/2008)|
|9.||Ge, Zhi-Dong: 1 article (01/2008)|
|10.||Mio, Yasushi: 1 article (01/2008)|
01/01/2008 - "Likewise, treating isolated mouse hearts with CP-532,903 (10, 30, or 100 nM) concentration dependently improved recovery of contractile function after 20 min of global ischemia and 45 min of reperfusion, including developed pressure and maximal rate of contraction/relaxation. "
01/01/2008 - "In in vivo ischemia/reperfusion experiments, pretreating mice with 30 or 100 microg/kg CP-532,903 reduced infarct size from 59.2 +/- 2.1% of the risk region in vehicle-treated mice to 42.5 +/- 2.3 and 39.0 +/- 2.9%, respectively. "
12/01/2003 - "Furthermore, administration of CP-532,903 (150 nM) at reperfusion also significantly reduced infarct size by 64% (P < 0.05 vs. control), which was not different (P > or = 0.05) from the cardioprotection provided by the same concentration of drug given before ischemia. "
12/01/2003 - "Five-minute perfusion with CP-532,903 before ischemia-reperfusion elicited a concentration-dependent reduction in infarct size in isolated hearts (EC50: 0.97 nM; maximum reduction in infarct size: 77%, P < 0.05 vs. control). "
01/01/2008 - "In isolated heart studies, protection provided by CP-532,903 and ischemic preconditioning induced by three brief ischemia/reperfusion cycles were lost in Kir6.2 KO mice lacking expression of the pore-forming subunit of the sarcolemmal ATP-sensitive potassium (K(ATP)) channel. "
01/01/2008 - "In both models of ischemia/reperfusion injury, CP-532,903 provided no benefit in studies using mice with genetic disruption of the A(3)AR gene, A(3) knockout (KO) mice. "
01/01/2008 - "We conclude that CP-532,903 is a highly selective agonist of the mouse A(3)AR that protects against ischemia/reperfusion injury by activating sarcolemmal K(ATP) channels."
01/01/2008 - "We examined the cardioprotective profile of the new A(3) adenosine receptor (AR) agonist CP-532,903 [N(6)-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] in an in vivo mouse model of infarction and an isolated heart model of global ischemia/reperfusion injury. "
01/01/2008 - "The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel."
|3.||Myocardial Ischemia (Ischemic Heart Diseases)
|2.||Adenosine Triphosphate (ATP)
|3.||Purinergic P1 Receptors (Adenosine Receptor)
|4.||Potassium Channels (Potassium Channel)